What is the current stock price of CorMedix Inc. (CRMD)?

As of the latest market data, CorMedix Inc. (CRMD) is trading at $7.39. The stock has seen a gain of 3.65% today.

Does CorMedix Inc. (CRMD) pay a dividend?

Based on current data, CorMedix Inc. does not have a confirmed active dividend policy.

What is the market cap of CorMedix Inc.?

The current market capitalization of CorMedix Inc. (CRMD) is approximately unavailable.

CRMD

CorMedix Inc.·Healthcare

7.39

3.647%(+0.26)

Market Closed

7.70

4.195%(+0.31)

After Hours

Last Updated: — ET

52W L: $6.1352W H: $17.43

CRMD NEWS

seekingalpha.com

Apr 8

CorMedix: A Shrinking Core And No Proven Second Engine

CorMedix is entering a post-TDAPA reset, with DefenCath revenue expected to decline materially and no proven second growth engine in place. FY26 guidance of ~$310M (midpoint) masks underlying deceleration, as DefenCath declines from $258.8M in FY25 to $150M–$170M in FY26, with the year-end run rate likely materially weaker heading into FY27. Rezzayo and DefenCath TPN offer long-term optionality but lack current financial contribution, while Melinta provides stability rather than growth.

globenewswire.com

Apr 7

CorMedix to Participate in Needham Virtual Healthcare Conference

PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming 25th Annual Needham Virtual Healthcare Conference taking place April 13 – 16, 2026.

Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2010-05-13

Beta

1.41

Websitewww.cormedix.com↗